SF | CARDIOLOGY
18
October 2021 | Vol. 21 No. 10 www.medicalacademic.co.za
This article was independently sourced by Specialist Forum.
Photo credit: Shutterstock.com
Is sequential treatment of dyslipidaemia effective in clinical practice?
This article is based on a presentation by Prof Evangelos Liberopoulos of the University of Ioannina (Greece) at the virtual European Society of Cardiology (ESC) congress held from 27-30 August. The topic of his presentation was Sequential Treatment Strategy in Dyslipidemia versus Earlier Use of Combination Therapies: Decision-Making Factors.1
H
igh low-density lipoprotein cholesterol (LDL-C) is associated with an increased risk of cardiovascular (CV) events. The cornerstone of secondary prevention is treatment with LDL lowering agents.1
LDL-C targets To lower the risk of CV events in very high-risk
patients, the ESC/European Atherosclerosis Society (EAS) dyslipidaemia guideline sets lower and more challenging LDL-C goals:2 » In primary prevention for individuals at very-high risk but without familial hypocholesteraemia (FH), an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.4mmol/L
» In primary prevention for individuals with FH at very-high risk, an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.4mmol/L » For patients with atherosclerotic CVD (ASCVD) who experience a second vascular event within two years (not necessarily of the same type as the first event) while taking
